Cytokinetics CYTK Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's operating income?
- Cytokinetics (CYTK) reported operating income of -$183.62M in Q1 2026.
- How has Cytokinetics's operating income changed year-over-year?
- Cytokinetics's operating income decreased by 18.0% year-over-year, from -$155.63M to -$183.62M.
- What is the long-term trend for Cytokinetics's operating income?
- Over 4 years (2021 to 2025), Cytokinetics's operating income has grown at a 34.6% compound annual growth rate (CAGR), from -$186.31M to -$612.26M.
- What does operating income mean?
- Profit or loss from core business operations before interest and taxes.
- How do you interpret operating income?
- Positive values indicate a self-sustaining business model, while negative values indicate that core operations are currently consuming capital.
- How does operating income compare across companies?
- Biotech companies in clinical stages often report negative operating income as they prioritize pipeline development over immediate profit.